PHOENIX: Low-dose daily aspirin almost doubles survival among patients with a range of gastrointestinal (GI) tract cancers, reveals an analysis of prescribing data.
In a study of almost 1400 GI cancer patients, the researchers found that among a subgroup of patients (8.3%) who took aspirin post-diagnosis, the 5-year overall survival was 75% among daily aspirin users compared to just more than 40% in those who did not take the drug.
Most patients had cancer of the colon (48%); the next most common sites were the rectum (42.8%) and the oesophagus (10.2%)…